Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNAIL1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous, Intraperitoneal, Parenteral
01
Overview
SNAIL1 siRNA is an experimental small interfering RNA (siRNA) designed to target and silence the SNAIL1 (SNAI1) gene, which encodes a zinc-finger transcription factor that acts as a master regulator of the epithelial-to-mesenchymal transition (EMT). By knocking down SNAIL1 expression, this research-stage compound suppresses cancer cell migration, proliferation, invasion, and metastasis, while inducing apoptosis. It has been widely utilized in preclinical and in vitro research across various oncology models, including breast cancer, bladder cancer, esophageal cancer, endometrial carcinoma, and melanoma. It is not commercially developed by a single pharmaceutical company and remains a laboratory research tool.
- Other names
- SNAI1 siRNASNAI-1 siRNASNAI 1 siRNASnail1 siRNASnail-1 siRNASnail 1 siRNA
02
Targets
SNAI1 (Snail family transcriptional repressor 1)
Beyond the preview
Go deeper on SNAIL1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNAIL1 siRNA.